Arcturus Therapeutics Stock (NASDAQ: ARCT)

Arcturus Therapeutics Stock (NASDAQ:ARCT), Trade Ideas

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARCT

BITF

CLSK

COIN

LOGI

MARA

SGMT

TBPH

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.

Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Analyst Color

Biotech

Equities

Health Care

Price Target

Initiation

Analyst Ratings

General

CSLLY

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.

Arcturus Therapeutics&#39; Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside

Intraday Update

ASTS

ATOM

AYTU

BTDR

CHGG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CRMD

DADA

EGOX

ELIQ

EVLO

FTCH

GLBE

GYRE

HRTX

HRYU

HSCS

ICVX

IHRT

INTA

INTZ

ISPR

JGGC

KBNT

KNTE

MGOL

MNTS

MRAI

MYTE

PRSO

RBOT

SDOT

SGMO

SHPW

SLDB

SLNH

SPRC

SXTP

TIVC

TRIP

TRKA

TSHA

VLCN

Vintage Wine Estates, Inc. - Common Stock

XAIR

Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.

Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics Holdings Inc

ARCTIC STAR EXPL CORP by Arctic Star Exploration Corp.

Arctic Star Exploration Corp

HC Wainwright &amp; Co. reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and maintains $60 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $60 Price Target

In the preceding three months, 4 analysts have released ratings for Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $63.25, a high estimate of $87.00, and a low estimate of $48.00. Witnessing a positive shift, the current average has risen by 14.31% from the previous average price target of $55.33.
<img src="https://www.benzinga.com/files/images/story/2024/1710158486_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Arcturus Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$87.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Ed Arce</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>John Abbott</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Arcturus Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Arcturus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Arcturus Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Arcturus Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ARCT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Arcturus Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Arcturus Therapeutics's Background</h2>
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
<h3>Arcturus Therapeutics's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Arcturus Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 224.45%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Arcturus Therapeutics's net margin excels beyond industry benchmarks, reaching -37.4%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Arcturus Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.74%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Arcturus Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -3.65%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Arcturus Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.18, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts

Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and raises the price target from $81 to $87.

Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Raises Price Target to $87

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and maintains $60 price target.

Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Arcturus Therapeutics beat estimated earnings by 68.0%, reporting an EPS of $-0.32 versus an estimate of $-0.99.
Revenue was down $126.30 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $1.08 which was followed by a 16.0% increase in the share price the next day.
Here's a look at Arcturus Therapeutics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.69</td>
<td>-0.21</td>
<td>0.06</td>
<td>0.98</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.61</td>
<td>-1.98</td>
<td>0.62</td>
<td>4.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>15.86M</td>
<td>48.50M</td>
<td>37.94M</td>
<td>72.68M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>45.14M</td>
<td>10.52M</td>
<td>80.28M</td>
<td>160.29M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Arcturus Therapeutics <a href="https://www.benzinga.com/quote/ARCT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Arcturus Therapeutics Q4 Earnings

Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) reported quarterly losses of $(0.320) per share which beat the analyst consensus estimate of $(0.760) by 57.89 percent. The company reported quarterly sales of $33.989 million which missed the analyst consensus estimate of $37.856 million by 10.22 percent. This is a 78.80 percent decrease over sales of $160.293 million the same period last year.

Earnings Beats

Earnings Misses

Arcturus Therapeutics Q4 2023 GAAP EPS $(0.320) Beats $(0.760) Estimate, Sales $33.989M Miss $37.856M Estimate

AFCG

ALIM

AMTX

AOUT

ARBE

ARHS

ASLE

ASPS

AVGO

BBAI

BBCP

BILI

BNED

BURL

CHMI

CIEN

CINT

CLAR

COOK

COST

CTOS

DBVT

DLTH

DOCU

DOMO

DSGR

DXPE

ELUT

EOLS

EVGN

EYPT

FCEL

FNKO

GEVO

GIFI

GRND

GRNT

GWRE

HBIO

ISDR

JYNT

LCTX

LMNR

LOCO

LUMO

LVRO

METC

MGNX

MKFG

MRVL

NAPA

NCSM

NDLS

NEPH

NINE

ONCT

ONCY

OPFI

OPTN

OWLT

PBPB

PHAT

PMTS

PRCH

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTS

PSFE

RDVT

REAX

REFR

RWAY

SDPI

SGHT

Earnings Scheduled For March 7, 2024

Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Here's what investors need to know before the announcement.
Analysts estimate that Arcturus Therapeutics will report an earnings per share (EPS) of $-0.99. 
Arcturus Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $1.08, which was followed by a 16.08% increase in the share price the next day.
Here's a look at Arcturus Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.69</td>
<td>-0.21</td>
<td>0.06</td>
<td>0.98</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.61</td>
<td>-1.98</td>
<td>0.62</td>
<td>4.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>16.0%</td>
<td>-19.0%</td>
<td>2.0%</td>
<td>30.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709737315_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Arcturus Therapeutics were trading at $37.56 as of March 05. Over the last 52-week period, shares are up 152.97%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ARCT/earnings">To track all earnings releases for Arcturus Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Arcturus Therapeutics

Arcturus Therapeutics Receives Orphan Medicinal Product Designation From The European Commission For ARCT-032 For Treatment Of Cystic Fibrosis

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and raises the price target from $40 to $48.

Citigroup Maintains Buy on Arcturus Therapeutics, Raises Price Target to $48

<ul>
<li>Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster</li>
<li>New data demonstrates continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response
<ul>
<li>These results follow approval of the world's first sa-mRNA COVID-19 vaccine for adults by Japan Ministry of Health, Labor and Welfare in November 2023</li>
</ul>
</li>
</ul>

Arcturus Therapeutics Announces New COVID-19 sa-mRNA Results

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.
Shares of Logitech International S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/logi#NASDAQ">LOGI</a>) fell sharply in today&rsquo;s pre-market trading after the company <a href="https://www.benzinga.com/quote/LOGI/earnings">reported third-quarter results.</a>
Logitech International posted quarterly earnings of $1.53 per share, versus market estimates of $1.17 per share. The company&rsquo;s quarterly sales came in at $1.25 billion versus expectations of $1.25 billion, according to data from <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
The company said it sees an annual sales decline of 6% to 7%, compared to prior estimates for a decline of 9% to 12%.
Logitech International shares dipped 7.4% to $88.83 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Sagimet Biosciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgmt#NASDAQ">SGMT</a>) shares fell 6.4% to $17.22 in pre-market trading. Sagimet Biosciences shares jumped 170% on Monday after the company announced denifanstat in the Phase 2b FASCINATE-2 clinical trial achieved statistically significant results on the primary and multiple secondary endpoints.</li>
<li>Arcturus Therapeutics Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arct#NASDAQ">ARCT</a>) fell 5% to $32.44 in pre-market trading after gaining 4% on Monday.</li>
<li>Coinbase Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) shares declined 4.4% to $122.63 in pre-market trading amid weakness in the price of Bitcoin.</li>
<li>CleanSpark, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clsk#NASDAQ">CLSK</a>) shares fell 3.7% to $6.84 in pre-market trading amid weakness in the price of Bitcoin.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) shares declined 3.6% to $16.02 in pre-market trading amid weakness in the price of Bitcoin.</li>
<li>Theravance Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbph#NASDAQ">TBPH</a>) shares fell 3.4% to $9.33 in pre-market trading.</li>
<li>Bitfarms Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bitf#NASDAQ">BITF</a>) shares slipped 3.3% to $2.02 in pre-market trading amid weakness in the price of Bitcoin.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36731525/fear-greed-index-remains-in-greed-zone-dow-settles-above-38-000"> Fear &amp; Greed Index Remains In &#39;Greed&#39; Zone; Dow Settles Above 38,000</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<ul>
<li>Data follow approval of the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine for Adults by Japan Ministry of Health, Labor and Welfare</li>
<li>The randomized, double-blind, active-controlled study, conducted at 11 sites in Japan, was designed to compare the immunogenicity and tolerability of the sa-mRNA vaccine ARCT-154 with Comirnaty&#xAE;</li>
<li>Phase 3 Study published in The Lancet Infectious Diseases</li>
</ul>
elicited a numerically higher immune response (meeting the non-inferiority criteria) against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty

CSL And Arcturus Therapeutics Announced The Publication In Lancet Infectious Diseases Of A Phase 3 Study Showing That A Booster Dose Of ARCT-154 Meet The Non-Inferiority Criteria

Canaccord Genuity&nbsp;has initiated coverage on&nbsp;Arcturus Therapeutics Holdings Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arct#NASDAQ">ARCT</a>), a player in the genetic medicine space.
Analysts Whitney Ijem and Joohwan Kim note that the company has developed proprietary and differentiated LNP delivery tech (LUNAR) and novel mRNA cargos (UNA, saRNA), allowing for&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/money/best-options-to-buy-this-week/" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">options</a>&nbsp;based on the application; hence, Arcturus has a pipeline of medicines across a range of indications.
Canaccord Genuity is particularly excited about ARCT-032, the company&#39;s inhaled mRNA therapeutic candidate for cystic fibrosis (CF).&nbsp;
Amidst the whirlwind of activities surrounding Arcturus, ARCT-032 seems to have operated quietly, progressing through Phase 1 and now administering doses to CF patients in Phase 1b.&nbsp;
Initial interim data is expected in the first half of 2024. A positive outcome would swiftly recalibrate the valuation of this program, given its prominence, significant unmet needs, and deep understanding of the disease.
The analyst initiates with a Buy and a&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/quote/ARCT/analyst-ratings" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">price target of $81</a>, an upside of over 200%.
The company is progressing with another rare disease program, ARCT-810, to treat ornithine transcarbamylase (OTC) deficiency. It is presently in the process of enrolling participants for a Phase 2 trial, and preliminary data is anticipated to be available next year.
Most recently,&nbsp;CSL Ltd&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cslly#OTC">CSLLY</a>) and Arcturus announced that Japan&#39;s Ministry of Health, Labor and Welfare approved ARCT-154, a self-amplifying mRNA COVID-19 vaccine for initial vaccination and booster for&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/11/n35976656/japans-ministry-of-health-labour-and-welfare-approves-csl-and-arcturus-therapeutics-arct-154-the-f" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">adults 18 years and older</a>.&nbsp;
Canaccord notes that while it may not captivate those accustomed to delving into rare diseases or genetic medicine, the narrative presented holds substantial strength, paralleled by robust economic considerations.
Price Action:&nbsp;ARCT shares are up 4.07% at $24.29 on the last check Wednesday.
Photo Via Company

Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside

Canaccord Genuity analyst Whitney Ijem initiates coverage on Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy rating.

Canaccord Genuity Initiates Coverage On Arcturus Therapeutics with Buy Rating

<h3>Understanding Value Stocks</h3>
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. 
<h2>Below is a list of notable value stocks in the healthcare sector:</h2>
<ol>
<li>Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) - P/E: 7.31</li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) - P/E: 1.0</li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) - P/E: 3.0</li>
<li>Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) - P/E: 6.62</li>
<li>Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) - P/E: 2.83</li>
</ol>
This quarter, Cross Country Healthcare experienced a decrease in earnings per share, which was $0.69 in Q2 and is now $0.39. Prenetics Global saw an increase in earnings per share from -0.75 in Q2 to $-0.05 now. Its most recent dividend yield is at 1.99%, which has decreased by 0.02% from 2.01% in the previous quarter.
Spero Therapeutics saw an increase in earnings per share from -0.23 in Q2 to $-0.06 now. Most recently, Arcturus Therapeutics reported earnings per share at $-0.61, whereas in Q2 earnings per share sat at $-1.98. Most recently, Zymeworks reported earnings per share at $-0.38, whereas in Q2 earnings per share sat at $-0.75. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

CCRN

SPRO

ZYME

5 Value Stocks In The Healthcare Sector

Japan's Ministry Of Health, Labour And Welfare Approves CSL And Arcturus Therapeutics' ARCT-154

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) with a Buy and maintains $51 price target.

HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $51 Price Target

First cystic fibrosis patient in Phase 1b study successfully completed two administrations of ARCT-032
On track to share interim Phase 1b data in H1 2024
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:<a href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company's product candidate ARCT-032 to treat cystic fibrosis (CF).
The FDA's Office of Orphan Products Development grants orphan status to drugs being developed to treat, prevent, or diagnose a rare disease or condition affecting fewer than 200,000 people in the United States. The designation provides significant incentives to promote the development of the drug including the potential for market exclusivity for seven years upon FDA approval, eligibility for tax credits for qualified clinical trials, waiver of Prescription Drug User Fee Act Application fee, and eligibility to receive regulatory guidance from the FDA in the design of an overall drug development plan.
"Orphan Drug Designation is a very important regulatory milestone in our development plan for ARCT-032," said Joseph Payne, President, and Chief Executive Officer of Arcturus Therapeutics. "We are executing diligently to accelerate ARCT-032 as a potential new treatment option for people with cystic fibrosis."
The first CF patient in our Phase 1b study successfully completed two administrations of ARCT-032. We remain on track to share interim Phase 1b data in H1 2024.

Arcturus Therapeutics Receives Orphan Drug Designation From The U.S. FDA For ARCT-032, For The Treatment Of Cystic Fibrosis

Shares of Shapeways Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shpw#NASDAQ">SHPW</a>) tumbled during Wednesday&rsquo;s session following downbeat results.
Shapeways Hldgs posted an adjusted loss of $1.36 per share, versus market expectations for a loss of 95 cents per share. The company&rsquo;s quarterly sales came in at $8.37 million versus estimates of $8.75 million.
Shapeways shares fell 20.8% to $2.36 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Taysha Gene Therapies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsha#NASDAQ">TSHA</a>) shares climbed 62.4% to $2.16 after the company reported third-quarter results.</li>
<li>Chemomab Therapeutics Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmmb#NASDAQ">CMMB</a>) shares jumped 55% to $0.9497 after the FDA granted CM-101 Fast Track designation for adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease.</li>
<li>Heron Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hrtx#NASDAQ">HRTX</a>) climbed 50.8% to $0.8143 after the company reported mixed third-quarter financial results and issued guidance.</li>
<li>Kinnate Biopharma Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/knte#NASDAQ">KNTE</a>) rose 47.7% to $2.32. The company&rsquo;s board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition of the company.</li>
<li>SciSparc Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprc#NASDAQ">SPRC</a>) gained 44.5% to $6.30. SciSparc said &#39;trial results indicated that SciSparc&#39;s proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer&#39;s patients who participated.&#39;</li>
<li>Evelo Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evlo#NASDAQ">EVLO</a>) gained 36% to $0.47.</li>
<li>Babcock &amp; Wilcox Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bw#NYSE">BW</a>) climbed 34.3% to $1.75.</li>
<li>Solid Biosciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sldb#NASDAQ">SLDB</a>) shares rose 32.7% to $2.83. Solid Biosciences announced IND clearance by the FDA for duchenne muscular dystrophy gene therapy candidate SGT-003.</li>
<li>MGO Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgol#NASDAQ">MGOL</a>) shares climbed 32.4% to $0.6566 after reporting a sharp rise in third-quarter sales.</li>
<li>Beyond Air, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xair#NASDAQ">XAIR</a>) gained 28% to $1.7920.</li>
<li>AST SpaceMobile, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asts#NASDAQ">ASTS</a>) rose 28% to $4.8262 following third-quarter results.</li>
<li>Arcturus Therapeutics Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arct#NASDAQ">ARCT</a>) shares climbed 25.2% to $24.34 after the company reported a narrower third-quarter loss.</li>
<li>Vicarious Surgical Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rbot#NYSE">RBOT</a>) rose 23.7% to $0.2726.</li>
<li>CorMedix Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crmd#NASDAQ">CRMD</a>) gained 23% to $3.85 as the company posted a narrower-than-expected third-quarter loss.</li>
<li>Soluna Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slnh#NASDAQ">SLNH</a>) climbed 22% to $2.9499 following third-quarter results.</li>
<li>Atomera Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atom#NASDAQ">ATOM</a>) gained 21% to $7.08. Atomera achieved revenue milestone under first commercial license agreement.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) climbed 20.5% to $11.45.</li>
<li>Dada Nexus Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dada#NASDAQ">DADA</a>) climbed 20% to $4.49 following third-quarter results.</li>
<li>Icosavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icvx#NASDAQ">ICVX</a>) gained 19.1% to $9.63 following strong quarterly earnings.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgmo#NASDAQ">SGMO</a>) jumped 19.1% to $0.4011.</li>
<li>Target Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgt#NYSE">TGT</a>) surged 18.2% to $130.89 after the company reported better-than-expected third-quarter financial results. The company will offer more than 10,000 items for holidays, that includes exclusives and many priced under $25.</li>
<li>iHeartMedia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ihrt#NASDAQ">IHRT</a>) gained 17.6% to $2.47. iHeartMedia and Global signed a multi-year podcast partnership deal in the UK, Ireland and US.</li>
<li>Farfetch Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ftch#NYSE">FTCH</a>) climbed 17.5% to $1.7750.</li>
<li>60 Degrees Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtp#NASDAQ">SXTP</a>) climbed 17% to $0.7605 as the company said that the FDA has granted a Type C meeting to consult on the path forward in developing the tafenoquine regimen of arakoda for hospitalized babesiosis patients.</li>
<li>V.F. Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vfc#NYSE">VFC</a>) climbed 14.3% to $17.80. JP Morgan upgraded VF from Underweight to Neutral and raised the price target from $15 to $19.</li>
<li>Chegg, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chgg#NYSE">CHGG</a>) gained 13.5% to $10.09. The company announced a $150 million buyback.</li>
<li>Heart Test Laboratories, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hscs#NASDAQ">HSCS</a>) shares gained 11% to $0.1999 after jumping 16% on Tuesday.</li>
<li>MYT Netherlands Parent B.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/myte#NASDAQ">MYTE</a>) rose 11% to $2.2750 after dipping 33% on Tuesday. Mytheresa is expected to release first quarter fiscal year 2024 financial results on Nov. 28, 2023</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) shares climbed 8.1% to $0.5805 after jumping 16% on Tuesday.</li>
<li>Tripadvisor, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trip#NASDAQ">TRIP</a>) gained 6.6% to $18.99. Bernstein upgraded TripAdvisor from Market Perform to Outperform.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sadot Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdot#NASDAQ">SDOT</a>) shares dipped 31.5% to $0.4903 after posting a wider third-quarter loss.</li>
<li>Electriq Power Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eliq#NASDAQ">ELIQ</a>) shares fell 30.3% to $0.5704 following third-quarter results.</li>
<li>Jaguar Global Growth Corporation I (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jggc#NASDAQ">JGGC</a>) shares fell 27.2% to $5.16.</li>
<li>Hanryu Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hryu#NASDAQ">HRYU</a>) fell 25.5% to $0.7001.</li>
<li>Global-e Online Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glbe#NASDAQ">GLBE</a>) fell 24.6% to $29.72 as the company reported third-quarter FY23 sales growth of 27% year-over-year, to $133.605 million, missing the consensus of $140.97 million.</li>
<li>ADDvantage Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aey#NASDAQ">AEY</a>) tumbled 23.4% to $0.2450 after posting a loss for the third quarter.</li>
<li>Vintage Wine Estates, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vwe#NASDAQ">VWE</a>) fell 23.3% to $0.5822 following quarterly results.</li>
<li>Kubient, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kbnt#NASDAQ">KBNT</a>) fell 22.8% to $0.1072 after the company announced it decided to voluntarily remove its stock and purchase warrants from the Nasdaq Capital Market due to noncompliance with listing requirements.</li>
<li>Aytu BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aytu#NASDAQ">AYTU</a>) declined 21.8% to $2.2987 following weak quarterly sales.</li>
<li>Troika Media Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trka#NASDAQ">TRKA</a>) dipped 20% to $1.24.</li>
<li>Ispire Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ispr#NASDAQ">ISPR</a>) declined 18.1% to $13.35 after jumping over 50% on Tuesday. The company reported a narrower loss for its first quarter.</li>
<li>Tivic Health Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tivc#NASDAQ">TIVC</a>) shares fell 18.1% to $1.7863 following downbeat sales results for the third quarter.</li>
<li>Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) dipped 15.2% to $4.24.</li>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) declined 14.1% to $0.6581.</li>
<li>Intrusion Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intz#NASDAQ">INTZ</a>) shares fell 13.7% to $0.4571 as the company reported downbeat third-quarter financial results.</li>
<li>Peraso Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prso#NASDAQ">PRSO</a>) fell 9.6% to $0.2079. Peraso recently posted upbeat quarterly results.</li>
<li>Marpai, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrai#NASDAQ">MRAI</a>) dipped 7.7% to $0.59. Marpai recently posted a narrower loss for the third quarter.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zim#NYSE">ZIM</a>) fell 7.1% to $7.25 following quarterly results.</li>
<li>Momentus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnts#NASDAQ">MNTS</a>) fell 6% to $3.3748 after reporting weak quarterly results.</li>
<li>Alcon Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alc#NYSE">ALC</a>) fell 5.3% to $71.01 after the company reported weak third-quarter sales and narrowed its full-year forecast.</li>
<li>Intapp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inta#NASDAQ">INTA</a>) shares declined 4.4% to $38.99. Intapp announced launch of underwritten secondary offering of aggregate of 5 million shares by selling stockholders.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/23/11/35801579/top-3-energy-stocks-that-may-implode-in-q4"> Top 3 Energy Stocks That May Implode In Q4</a>

Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session